Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review
Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic chemotherapy regimens have not produced optimal long-term outcomes, and many urothelial cancer patients have comorbidities that disqualify them as chemotherapy candidates. In recent years, a plethora of nov...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.705294/full |
| _version_ | 1818640921008275456 |
|---|---|
| author | Blessie Elizabeth Nelson Angelina Hong Bagi Jana |
| author_facet | Blessie Elizabeth Nelson Angelina Hong Bagi Jana |
| author_sort | Blessie Elizabeth Nelson |
| collection | DOAJ |
| description | Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic chemotherapy regimens have not produced optimal long-term outcomes, and many urothelial cancer patients have comorbidities that disqualify them as chemotherapy candidates. In recent years, a plethora of novel therapeutic agents that target diverse molecular pathways has emerged as alternative treatment modalities for not only metastatic urothelial carcinoma, but also for muscle-invasive bladder cancer and non-muscle invasive bladder cancer in adjuvant and definitive settings. This review paper aims to discuss the various categories of therapeutic agents for these different types of urothelial cancer, discussing immunotherapy, antibody-drug conjugates, kinase inhibitors, CAR-T cell therapy, peptide vaccination, and other drugs targeting pathways such as angiogenesis, DNA synthesis, mTOR/PI3K/AKT, and EGFR/HER-2. |
| first_indexed | 2024-12-16T23:18:57Z |
| format | Article |
| id | doaj.art-87ca4316cf5a46d38baf68045365ce0b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-16T23:18:57Z |
| publishDate | 2021-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-87ca4316cf5a46d38baf68045365ce0b2022-12-21T22:12:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-08-011110.3389/fonc.2021.705294705294Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature ReviewBlessie Elizabeth Nelson0Angelina Hong1Bagi Jana2Department of Hematology and Oncology, University of Texas Medical Branch, Galveston, TX, United StatesSchool of Medicine, University of Texas Medical Branch, Galveston, TX, United StatesDepartment of Hematology and Oncology, MD Anderson Cancer Center, Houston, TX, United StatesUrothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic chemotherapy regimens have not produced optimal long-term outcomes, and many urothelial cancer patients have comorbidities that disqualify them as chemotherapy candidates. In recent years, a plethora of novel therapeutic agents that target diverse molecular pathways has emerged as alternative treatment modalities for not only metastatic urothelial carcinoma, but also for muscle-invasive bladder cancer and non-muscle invasive bladder cancer in adjuvant and definitive settings. This review paper aims to discuss the various categories of therapeutic agents for these different types of urothelial cancer, discussing immunotherapy, antibody-drug conjugates, kinase inhibitors, CAR-T cell therapy, peptide vaccination, and other drugs targeting pathways such as angiogenesis, DNA synthesis, mTOR/PI3K/AKT, and EGFR/HER-2.https://www.frontiersin.org/articles/10.3389/fonc.2021.705294/fullurothelial carcinomamolecular targetsFDA approvalsbladder cancerclinical trialstargeted therapy |
| spellingShingle | Blessie Elizabeth Nelson Angelina Hong Bagi Jana Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review Frontiers in Oncology urothelial carcinoma molecular targets FDA approvals bladder cancer clinical trials targeted therapy |
| title | Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review |
| title_full | Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review |
| title_fullStr | Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review |
| title_full_unstemmed | Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review |
| title_short | Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review |
| title_sort | elucidation of novel molecular targets for therapeutic strategies in urothelial carcinoma a literature review |
| topic | urothelial carcinoma molecular targets FDA approvals bladder cancer clinical trials targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.705294/full |
| work_keys_str_mv | AT blessieelizabethnelson elucidationofnovelmoleculartargetsfortherapeuticstrategiesinurothelialcarcinomaaliteraturereview AT angelinahong elucidationofnovelmoleculartargetsfortherapeuticstrategiesinurothelialcarcinomaaliteraturereview AT bagijana elucidationofnovelmoleculartargetsfortherapeuticstrategiesinurothelialcarcinomaaliteraturereview |